Abata Therapeutics Appoints Sandy Lazzari as Chief People Officer

Flare Therapeutics Appoints Adrian Jubb as Chief Medical Officer

Ambys Medicines Expands Leadership Team with Key Appointments 
in Human Resources and Finance Functions

Magenta Therapeutics Focuses R&D And Operational Spending, Reduces Workforce And Extends Cash Runway

Rheos Medicines Announces New Scientific Advisory Board Members

Rheos Medicines Appoints Katerina Leftheris, Ph.D., as SVP of Drug Discovery and Nabil Uddin, Pharm.D., as VP of Strategy and Business Development

Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

Asher Bio to Present New Preclinical Data Demonstrating Differentiated Profile of AB248, its Lead Cis-targeted IL-2 Immunotherapy, at AACR Annual Meeting

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

Tango Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Highlights

Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

Goldfinch Bio to Host Virtual Event on Unmet Need in Focal Segmental Glomerulosclerosis (FSGS) and GFB-887 as a Novel Kidney Precision Medicine Candidate

Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference

insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022

Tango Therapeutics Announces Presentation Of TNG908 Preclinical Combination Data At 2022 ESMO Targeted Anticancer Therapies Congress

Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis (FSGS)

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD

Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease

Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed To Voyager Therapeutics’ Board Of Directors And Newly Formed Executive Committee

Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

Septerna Launches with $100 Million Series A Financing to Expand the Frontier of GPCR-targeted Medicines using the Native Complex™ Platform

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Asher Bio Expands Leadership Team with Three Key Appointments

Ambys Medicines Appoints Dr. Corinne Foo-Atkins as Chief Strategy Officer

insitro Announces Leadership Team Expansion to Support Advancement of Machine Learning Enabled Drug Discovery and Development Efforts

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

Allena Pharmaceuticals Provides Clinical and Corporate Update

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform

Asher Bio Showcases Versatility and Broad Applicability of Cis-Targeting Technology for Precision Immunotherapies at Antibody Engineering Conferences